843608-45-7

Usage

Uses

Used in Organic Synthesis:
1-(3-BROMO-PHENYL)-2,2,2-TRIFLUORO-ETHYLAMINE is used as a key intermediate in organic synthesis for its ability to participate in various chemical reactions, facilitating the creation of a broad range of complex organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(3-BROMO-PHENYL)-2,2,2-TRIFLUORO-ETHYLAMINE is used as a building block for the development of new pharmaceuticals. Its unique structure allows for the design of innovative drug candidates with potential therapeutic applications.
Used in Chemical Reactions:
1-(3-BROMO-PHENYL)-2,2,2-TRIFLUORO-ETHYLAMINE is utilized in a variety of chemical reactions due to its reactivity, making it a valuable asset in the synthesis of specialty chemicals and materials for different industries.

Upstream product

• 655-26-5 m-bromotrifluoroacetone 

Relevant academic research and scientific papers

IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.

COMPOSITIONS AND METHODS FOR INHIBITING BMP

The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.